James J. Devlin

6.5k total citations · 2 hit papers
89 papers, 4.6k citations indexed

About

James J. Devlin is a scholar working on Genetics, Surgery and Molecular Biology. According to data from OpenAlex, James J. Devlin has authored 89 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 23 papers in Surgery and 23 papers in Molecular Biology. Recurrent topics in James J. Devlin's work include Genetic Associations and Epidemiology (20 papers), Lipoproteins and Cardiovascular Health (19 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). James J. Devlin is often cited by papers focused on Genetic Associations and Epidemiology (20 papers), Lipoproteins and Cardiovascular Health (19 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). James J. Devlin collaborates with scholars based in United States, United Kingdom and Netherlands. James J. Devlin's co-authors include Patricia E. Devlin, Dov Shiffman, Charles M. Rowland, Judy Z. Louie, Joseph J. Catanese, Lance A. Bare, Olga A. Iakoubova, Carmen H. Tong, May M. Luke and Olle Melander and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

James J. Devlin

89 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Random Peptide Libraries: a Source of Specific Protein Binding Molecules

1990 740 citations James J. Devlin, Patricia E. Devlin et al. profile →
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

2015 455 citations Jessica L. Mega, Nathan O. Stitziel et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James J. Devlin United States	34	1.6k	1.2k	1.2k	920	814	89	4.6k
Bernhard H. Rauch Germany	37	1.7k 1.0×	248 0.2×	589 0.5×	1.2k 1.3×	331 0.4×	162	4.5k
Kevin Horgan United States	34	1.0k 0.6×	812 0.7×	3.2k 2.7×	533 0.6×	820 1.0×	63	9.1k
Giulia Chiesa Italy	35	1.5k 0.9×	406 0.3×	2.1k 1.9×	610 0.7×	136 0.2×	114	4.5k
Chiang‐Ching Huang United States	32	3.5k 2.1×	653 0.6×	442 0.4×	641 0.7×	243 0.3×	91	6.2k
Randall F. Holcombe United States	38	2.4k 1.4×	364 0.3×	567 0.5×	401 0.4×	416 0.5×	147	5.6k
Tomoko Takano Canada	42	2.4k 1.5×	538 0.5×	536 0.5×	248 0.3×	184 0.2×	145	6.0k
Cyril Mamotte Australia	26	798 0.5×	390 0.3×	557 0.5×	394 0.4×	146 0.2×	67	3.4k
John F. Smyth United Kingdom	52	3.7k 2.3×	1.1k 0.9×	941 0.8×	185 0.2×	260 0.3×	202	8.2k
Masato Sakon Japan	54	3.4k 2.0×	486 0.4×	2.4k 2.1×	539 0.6×	385 0.5×	383	9.9k
Paul F. Bray United States	53	2.0k 1.2×	1.1k 0.9×	1.3k 1.1×	2.9k 3.2×	235 0.3×	175	8.8k

Countries citing papers authored by James J. Devlin

Since Specialization

Citations

This map shows the geographic impact of James J. Devlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James J. Devlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James J. Devlin more than expected).

Fields of papers citing papers by James J. Devlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James J. Devlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James J. Devlin. The network helps show where James J. Devlin may publish in the future.

Co-authorship network of co-authors of James J. Devlin

This figure shows the co-authorship network connecting the top 25 collaborators of James J. Devlin. A scholar is included among the top collaborators of James J. Devlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James J. Devlin. James J. Devlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leu, Jocelyn H., Xin Miao, Kevin Shalayda, et al.. (2023). A Phase 1 First‐in‐Human Pharmacokinetic and Pharmacodynamic Study of JNJ‐64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase. Clinical Pharmacology in Drug Development. 12(6). 611–624. 2 indexed citations

Li, Yonghong, et al.. (2020). Cost-effectiveness of nucleic acid amplification testing to guide treatment for vaginitis: a decision-modeling analysis. Diagnostic Microbiology and Infectious Disease. 98(2). 115119–115119. 3 indexed citations

Li, Yonghong, Lori Anderson, Edward I. Ginns, & James J. Devlin. (2017). Cost Effectiveness of Karyotyping, Chromosomal Microarray Analysis, and Targeted Next-Generation Sequencing of Patients with Unexplained Global Developmental Delay or Intellectual Disability. Molecular Diagnosis & Therapy. 22(1). 129–138. 21 indexed citations

Li, Yonghong, André R. Arellano, Lance A. Bare, et al.. (2017). A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer. Value in Health. 20(4). 547–555. 34 indexed citations

Mega, Jessica L., Nathan O. Stitziel, J. G. Smith, et al.. (2015). Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. The Lancet. 385(9984). 2264–2271. 455 indexed citations breakdown →

Shiffman, Dov, Marco Pérez, Lance A. Bare, et al.. (2015). Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. BMC Cardiovascular Disorders. 15(1). 104–104. 4 indexed citations

Rowland, Charles M., Clive R. Pullinger, May M. Luke, et al.. (2014). Lipoprotein (a), LPA Ile4399Met, and Fibrin Clot Properties. Thrombosis Research. 133(5). 863–867. 27 indexed citations

Vlieg, Astrid van Hylckama, Linda E. Flinterman, Lance A. Bare, et al.. (2013). Assessment of the risk of recurrent venous thrombosis using a genetic risk score comprising five genetic markers. Journal of Thrombosis and Haemostasis. 11. 27–28. 2 indexed citations

Shiffman, Dov, Ellen S. O’Meara, Charles M. Rowland, et al.. (2011). The contribution of a 9p21.3 variant, a KIF6 variant, and C-reactive protein to predicting risk of myocardial infarction in a prospective study. BMC Cardiovascular Disorders. 11(1). 10–10. 11 indexed citations

10.

Trompet, Stella, Anton JM de Craen, Iris Postmus, et al.. (2011). Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC Medical Genetics. 12(1). 131–131. 25 indexed citations

11.

Bare, Lance A., Edward Ruiz-Narváez, Carmen H. Tong, et al.. (2010). Investigation of KIF6 Trp719Arg in a Case-Control Study of Myocardial Infarction: A Costa Rican Population. PLoS ONE. 5(9). e13081–e13081. 13 indexed citations

12.

Shiffman, Dov, Judy Z. Louie, Charles M. Rowland, et al.. (2010). Single variants can explain the association between coronary heart disease and haplotypes in the apolipoprotein(a) locus. Atherosclerosis. 212(1). 193–196. 10 indexed citations

13.

Bezemer, Irene D., André R. Arellano, Carmen H. Tong, et al.. (2009). F9 Malmo, factor IX and deep vein thrombosis. Haematologica. 94(5). 693–699. 19 indexed citations

14.

Mega, Jessica L., Olga A. Iakoubova, James J. Devlin, et al.. (2009). Abstract 5765: 9p21 Genetic Variant and Benefit From Intensive Statin Therapy After an Acute Coronary Syndrome. Circulation. 120(suppl_18). 1 indexed citations

15.

Li, Yonghong, Irene D. Bezemer, Charles M. Rowland, et al.. (2009). Genetic variants associated with deep vein thrombosis: the F11 locus. Journal of Thrombosis and Haemostasis. 7(11). 1802–1808. 87 indexed citations

16.

Shiffman, Dov, Daniel I. Chasman, Robert Y.L. Zee, et al.. (2008). A Kinesin Family Member 6 Variant Is Associated With Coronary Heart Disease in the Women’s Health Study. Journal of the American College of Cardiology. 51(4). 444–448. 65 indexed citations

17.

Iakoubova, Olga A., Marc S. Sabatine, Charles M. Rowland, et al.. (2008). Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes. Journal of the American College of Cardiology. 51(4). 449–455. 111 indexed citations

18.

Bare, Lance A., Alanna C. Morrison, Charles M. Rowland, et al.. (2007). Five common gene variants identify elevated genetic risk for coronary heart disease. Genetics in Medicine. 9(10). 682–689. 75 indexed citations

19.

Blasko, Eric, Charles B. Glaser, James J. Devlin, et al.. (2002). Mechanistic Studies with Potent and Selective Inducible Nitric-oxide Synthase Dimerization Inhibitors. Journal of Biological Chemistry. 277(1). 295–302. 83 indexed citations

20.

Devlin, Patricia E., et al.. (1988). Alteration of amino-terminal codons of human granulocyte-colony-stimulating factor increases expression levels and allows efficient processing by methionine aminopeptidase in Escherichia coli. Gene. 65(1). 13–22. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact